Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Laklin
- Development stage
- Unknown
- Lead developer
- OMNIFARMA
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Laklin is a probiotic dietary supplement developed by Omnifarma Kiev, specifically formulated to support and restore the urogenital and intestinal microflora in women. It contains a concentrated blend of two clinically studied probiotic strains: *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14. These microorganisms are capable of surviving gastrointestinal transit and colonizing the vaginal mucosa. Once established, they produce lactic acid, hydrogen peroxide, and bacteriocins, which lower the local pH and create an environment hostile to pathogenic bacteria and yeast, such as *Gardnerella vaginalis* and *Candida albicans*. Laklin is primarily indicated for the prevention and adjunctive treatment of bacterial vaginosis and vaginal candidiasis, as well as for maintaining overall urogenital health and microbial balance.
- Brand names
- LaklinЛаклін
Beyond the preview
Go deeper on Laklin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laklin.